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Abstract
Background Distal renal tubular acidosis (dRTA), due to impaired acid secretion in the urine, can lead to severe long-term
consequences. Standard of care (SoC) oral alkalizers, requiring several daily intakes, are currently used to restore normal plasma
bicarbonate levels. A new prolonged-release formulation, ADV7103, has been developed to achieve a sustained effect with an
improved dosing scheme.
Methods In a multicenter, open-label, non-inferiority trial (n = 37), patients with dRTA were switched from SoC to ADV7103.
Mean plasma bicarbonate values and proportion of responders during steady state therapy with both treatments were compared,
as were other blood and urine parameters, as well as acceptability, tolerability, and safety.
Results When switching from SoC to ADV7103, the number of daily intakes was reduced from a median of three to twice daily.
Mean plasma bicarbonate was increased and non-inferiority of ADV7103 was demonstrated (p < 0.0001, per protocol), as was
statistical superiority (p = 0.0008, intention to treat [ITT]), and the response rate increased from 43 to 90% with ADV7103
(p < 0.001, ITT). Urine calcium/citrate ratio was reduced below the threshold for risk of lithogenesis with ADV7103 in 56% of
previously non-responders with SoC (p = 0.021, ITT). Palatability was improved (difference [95% CI] of 25 [10.7, 39.2] mm)
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and gastrointestinal discomfort was reduced (difference [95% CI] of − 14.2 [− 25.9, − 2.6] mm) with ADV7103.
Conclusions Plasma bicarbonate levels and response rate were significantly higher with ADV7103 than with SoC. Urine
calcium/citrate ratio, palatability, and gastrointestinal safety were significantly improved, supporting the use of ADV7103 as
first-line treatment for dRTA.
Trial registration Registered as EudraCT 2013-002988-25 on the 1st July 2013
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Introduction
Distal renal tubular acidosis (dRTA) is a rare disorder due to an
impaired net secretion of acid by the distal tubule, resulting in
hyperchloremic metabolic acidosis, often combined with hypo-
kalemia as a result of renal potassium wasting [1–3]. Distal
RTA arises when transporters or transcription factors implicat-
ed in renal proton secretion are genetically altered [4–6] or
affected as a consequence of an autoimmune disease [7–9].
Failure to thrive is the most common presentation of dRTA
in infants and children [10]. If not adequately treated, dRTA
causes great damage to bone and kidney [2, 11–15]. In some
cases, particularly when associated to an autoimmune disease,
dRTA may also present as a metabolic emergency, including
manifestations such as hypokalemic paralysis, metabolic co-
ma, and, in extreme cases, death [7, 10].
The standard of care (SoC) therapy consists of administra-
tion of oral alkalizing agents, usually as immediate-release
bicarbonate and/or citrate salts, and potassium supplements
if required [2, 4, 13, 16]. Drug doses need to be adjusted to
maintain normal plasma bicarbonate concentrations [17].
Current treatments are characterized by poor efficacy, inconve-
nient dosing schemes requiring multiple day and night adminis-
trations, gastrointestinal discomfort, bad taste, and poor adherence,
with only half of patients achieving correct metabolic control ac-
cording to a recent report in patients with primary dRTA [11].
ADV7103 is an innovative, prolonged-release oral granule
formulation (2 mm tablets) combining the advantages of po-
tassium citrate and potassium bicarbonate [18]. It has been
developed with the aim to improve the absorption profile of
the alkalizing agents, delivering sustained efficacy over 12 h,
and thus reducing administration to only two intakes per day.
The aim of the study was to evaluate short-term efficacy, ac-
ceptability, tolerability, and safety of ADV7103 in comparison to
current SoC treatments in adult and pediatric patients with dRTA.
Materials and methods
Study population and design
A multicenter, open-label, non-randomized, non-inferiority
phase II/III trial (EudraCT 2013-002988-25), in which adult
and pediatric patients with dRTA were switched from SoC to
ADV7103 treatment, was performed according to a protocol
discussed with the European Medicines Agency (EMA), con-
sidering the small size of the target population.
During the study, male and female patients (aged 6 months
to 55 years old), with acquired or inherited forms of dRTA,
were enrolled.
Patients were excluded from the study based on the follow-
ing criteria: unusual additional proximal tubular signs,
hyperkalemia (plasma potassium > 5.0 mmol/L), moderate
or severe kidney impairment (GFR < 45 mL/min/1.73 m2),
or any other condition that could be negatively affected by
the study medication or that could affect the study medication.
Pa t ien ts rece iv ing potass ium-spar ing d iu re t ics ,
angiotensin-converting enzyme inhibitors, angiotensin II re-
ceptor antagonists, or tacrolimus were also ruled out.
Enrolment was performed according to a staggered ap-
proach, where review of safety/tolerability data of older pa-
tients completing the study by a Data Safety Monitoring
Board allowed validation of subsequent enrolment of younger
patients.
Patients participated for three consecutive study periods
(Fig. 1):
– Period I: Five-day steady state treatment with SoC and
any potassium supplements respecting usual therapeutic
dose and dosing schemes.
– Period II: Titration phase aimed at determining the thera-
peutic ADV7103 dose.
– Period III: Five-day steady state treatment with
ADV7103 at the therapeutic dose.
For titration of ADV7103 during period II, dose increments
of 0.5, 1.0, or 1.5 mEq/kg/day were considered, without ex-
ceeding 10 mEq/kg/day.
Plasma bicarbonate and plasma potassium
The primary endpoint was the mean pre-morning dose level of
plasma bicarbonate, over three consecutive days (day 2, day 3,
and day 4) on steady state therapy (see Fig. 1). Patients were
considered non-responders when their mean plasma
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bicarbonate concentration was below the lower normal value
of the local laboratory. As a secondary evaluation, patients
were considered non-responders when any single value of
plasma bicarbonate was below the lower normal value, as an
indicator of the robustness of metabolic control.
Plasma potassium was evaluated using the same blood
samples, as well as samples drawn during day 5 (Fig. 1).
Patients were considered as hypokalemic when any single
value was below the normal range of the local laboratory.
Detailed information about the methods used for plasma
bicarbonate and plasma potassium and the normal ranges de-
fined by each local laboratory is provided as supplementary
information.
Urine parameters
Urine parameters were determined during steady state with
SoC and with ADV7103 on urine samples collected before
treatment administration on day 4 and day 5 (Fig. 1).
Calcium and citrate to creatinine ratios were calculated and
expressed in mmol/mmol. Hypercalciuria was considered
when patients presented at least one episode of the urine cal-
cium to creatinine ratio (UCa/UCr) above the normal values
previously defined according to age and gender [19, 20].
Hypocitraturia was considered when patients presented at
least one episode of the urine citrate to creatinine ratio (UCi/
UCr) below the normal values found in the literature accord-
ing to age and gender [21].
Increased risk of stone formation was considered in pa-
tients presenting at least one episode of the urine calcium to
citrate ratio (UCa/UCi) above the reported threshold to eval-
uate the risk of lithogenesis of 3 mmol/mmol [22]. Although
this index is not as relevant in young children as in older
children and adults, it was considered to indicate a more equil-
ibrated ratio between calcium and citrate excretion.
Detailed information about the normal values used for
urine parameters is provided as supplementary information.
Palatability and acceptability
Palatability was evaluated by the end of both steady state
treatment periods using a self-rated 100 mm visual analogue
scale (VAS) in adults and adolescents (score of 0 meaning
“dislike very much” and a score of 100 “like very much”),
an equivalent 100 mm parent-rated VAS in children < 4 years
of age, and a validated self-rated 5-point facial hedonic scale
(FHS) in children 4–11 years of age (with the support of their
parents if required). FHS scores were converted to VAS scores
(and vice-versa) so that all patients could be assessed together
despite the differences in the evaluation methods.
Additionally, scores for ease of administration and ease of
swallowing were evaluated similarly with appropriate
self-rated or parent-rated 100-mm VAS scales (a score of 0
meaning “very difficult” and a score of 100 “very easy”).
Safety and tolerability
Adverse events (AEs) were recorded and graded according to
their severity and causal relationship with the treatments. Any
abnormal values on blood or urine parameters, physical ex-
amination, and vital signs were also recorded. Hyperkalemia
was specifically followed.
Gastrointestinal tolerability was evaluated at the end of both
steady state treatment periods with appropriate (self-rated or
parent-rated) 100 mm VAS, except for children 4–11 years of
age, for whom a validated self-rated 5-point FHSwas used. FHS
scores were converted to VAS scores (and vice-versa).
Statistical methods
All patients with at least one efficacy assessment were included
in the intent-to-treat (ITT) analysis set. All patients who com-
pleted the study with no major protocol deviations impacting
on efficacy were included in the per protocol (PP) analysis set.
Missing plasma bicarbonate values for calculation of the
primary endpoint were replaced by additional values obtained
Fig. 1 Design of the study. D day, h hour, PC phone call, SP study period, SS steady state, t0 timepoint before first morning dose
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on day 1 or day 5 of the same period, as long as they were
quantified under exactly the same conditions (i.e., before
morning dose, same laboratory, same analysis method, same
equipment, and same normal ranges). The mean value was
calculated when at least one of the three values was available.
Individual mean values of plasma bicarbonate obtained
with ADV7103 and SoC were first compared in a
non-inferiority analysis in the PP set. At least 24 evaluable
patients were required to have at least 80% power for the
primary non-inferiority assessment, assuming a one-sided
paired t test at the 2.5% significance level, with a standard
deviation of 4.1 mmol/L and a non-inferiority margin of −
2.5 mmol/L. Non-inferiority of ADV7103 was considered
when the lower, one-sided 97.5% of the mean difference be-
tween ADV7103 and SoC lay entirely on the positive side of
the non-inferiority margin.
A mixed-effects analysis of variance (ANOVA) in the ITT
set, which included the treatment as a fixed effect and the
patient as a random effect, was used to assess superiority.
This was done after non-inferiority was declared, in line with
the EMA and the FDA recommendations [23, 24]. Values of
least squares (LS) mean, standard error (SE), and two-sided
95% confidence interval (CI) were reported for the difference
between ADV7103 and SoC.
Proportions of non-responders and responders were report-
ed in contingency tables for the different blood and urine
parameters evaluated with SoC and ADV7103. In order to
compare both treatments, McNemar’s test was used (signifi-
cance level α = 5%). If the p value was significant for a given
parameter, the null hypothesis of homogeneity of the propor-
tions was rejected.
The number/proportion of patients presenting AEs, inci-
dence, and severity of these AEs and incidence of abnormal
values on safety laboratory parameters, physical examination,
and vital signs were reported. Descriptive analyses were per-
formed for each treatment, overall and by age group in the
safety analysis (SA) set (patients who received at least one
dose of any of the study treatments).
The analysis of gastrointestinal tolerability and treatment
acceptability was performed using a mixed model with treat-
ment as a fixed factor and an unstructured covariance matrix
for the repeated measures by patient and LS mean, SE and
two-sided 95% CI values were reported for the difference
between treatments in the acceptability analysis (AA) set (pa-
tients who received at least one dose of any of the study treat-
ments and with at least one acceptability assessment).
Results
A total of 37 patients (36 with inherited dRTA and 1 with
dRTA as a consequence of Sjögren’s disease) were enrolled
in 13 different centers in France, Serbia, and Slovakia. The
study took place between September 2014 and May 2016.
Patient enrolment/completion and population characteristics
are summarized in Table 1. Five (13.5%) patients dropped
out prematurely (a child due to the high number of blood tests
needed, an infant, a toddler, an adolescent due to problems in
taking ADV7103 treatment, and an adolescent due to lack of
efficacy with ADV7103) and 32 patients completed the three
study periods.
Description of treatments
A great diversity of SoC products in the form of
immediate-release formulations was observed. Almost half
of the patients (48.6%) took more than one alkalizing product.
Three patients (8.1%) received potassium chloride as a sup-
plement to their SoC treatment. A large proportion of patients
(62.2%) were receiving sodium salts.
The number of daily intakes with SoC ranged between 3
and 6 in 32 patients (86.5%) and 10 patients (27%) had to take
their medication during night-time, which was particularly
frequent in children. Mean ± SD alkali doses prescribed with
SoC were 1.99 ± 1.54, 2.20 ± 1.41, 2.70 ± 1.23, and 5.27 ±
2.54 mEq/kg/day, in adults, adolescents, children, and in-
fants/toddlers, respectively.
In contrast, only two intakes of ADV7103 (morning and
evening) were given. The mean ± SD alkali doses prescribed
with ADV7103 were 1.74 ± 1.05, 2.79 ± 1.74, 3.80 ±
1.15, and 6.11 ± 2.26mEq/kg/day, in adults, adolescents, chil-
dren, and infants/toddlers), respectively.
Plasma bicarbonate levels
An improvement of plasma bicarbonate levels and less vari-
ability were observed with ADV7103 compared to SoC
(Fig. 2). The overall mean ± SD plasma bicarbonate values
were 21.7 ± 3.1 and 23.1 ± 1.6 mmol/L, respectively, with
SoC (n = 29) and ADV7103 (n = 30) considering the PP set,
and 21.2 ± 3.1 and 23.0 ± 1.6 mmol/L, respectively, with SoC
(n = 34) and ADV7103 (n = 31) considering the ITT set.
As the non-inferiority of ADV7103 vs. SoC was demon-
strated considering the mean plasma bicarbonate values (dif-
ference (95% CI) of 1.42 (0.41, 2.43), p < 0.0001, PP set), a
subsequent superiority analysis was performed, also showing
a statistically significant difference in favor of ADV7103 (LS
mean difference (95% CI) of 1.64 (0.67, 2.60), p = 0.0008,
ITT set).
Non-responder/responder analyses for mean plasma bicar-
bonate values considering the ITT set (n = 30) indicated that
only 13 (43.3%) patients treated with SoC presented mean
plasma bicarbonate values above the lower normal value, while
27 (90%) had normal values with ADV7103. A total of 14
(82.4%) patients from the 17 non-responders with SoC became
responders when switching to ADV7103, while among the 3
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non-responders with ADV7103, none was previously respond-
er with SoC (Table 2). The difference in the proportions of
responders/non-responders between both treatments was statis-
tically significant (McNemar’s p < 0.001, ITT set).
In the particular case of the adult female presenting an
acquired form of dRTA (due to Sjögren’s disease), mean plas-
ma bicarbonate levels were in the normal range with both SoC
and ADV7103 (22.7 ± 1.5 and 22.7 ± 0.6 mmol/L,
respectively).
Plasma potassium levels
The mean plasma potassium levels obtained during steady
state treatment with SoC and ADV7103 are shown in Fig. 3,
Table 1 Patient disposition and summary of demographic data by age group and overall
Adults ≥ 18 years Adolescents 12–17 years Children 4–11 years Infants and toddlers 0.5–3 years Overall
n patients enrolled 7 10 15 5 37
n(%) females 5 (71%) 8 (80%) 9 (60%) 1 (20%) 23 (62%)
n(%) males 2 (29%) 2 (20%) 6 (40%) 4 (80%) 14 (38%)
Age (years)
Mean (SD) 23.3 (9.9) 14.0 (1.7) 7.3 (2.4) 2.6 (1.1) 11.5 (8.2)
Median (range) 19.3 (19–46) 13.6 (12–17) 7.4 (5–12) 3.0 (1–4) 11.5 (1–46)
Weight (kg)
Mean (SD) 69.1 (22.6) 43.7 (7.6) 26.5 (12.5) 13.4 (3.8) 37.4 (22.3)
Median (range) 60.5 (51–114) 41.9 (32–57) 23.3 (12–54) 12.5 (9–19) 39.0 (9–114)
Height (cm)
Mean (SD) 160.3 (7.5) 156.6 (10.0) 119.7 (16.5) 90.9 (11.1) 133.5 (27.8)
Median (range) 164 (149–168) 157 (139–170) 117 (91–154) 94 (75–102) 139 (75–170)
BMI (kg/m2)
Mean (SD) 26.6 (7.1) 17.8 (2.6) 17.5 (3.7) 16.0 (1.4) 19.1 (5.4)
Median (range) 23.8 (20–41) 16.7 (15–23) 15.9 (13–24) 15.9 (14–18) 16.8 (13–41)
n patients SPI completed 7 10 14 4 35
n patients SPIII completed 7 8 14 3 32
n drop-outs 0 2 1 2 5
BMI body mass index, SD standard deviation, SP study period
Fig. 2 Steady state mean (± SD)
plasma bicarbonate levels in the
different age groups before
administration of the first
morning dose of SoC (multiple
daily intakes) and ADV7103
(morning and evening), ITT set.
Blue bars: SoC, orange bars:
ADV7103
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with overall mean ± SD values of 3.8 ± 0.4 under SoC and 4.0
± 0.4 with ADV7103 in the ITT set (n = 34).
The response rate for potassium levels in the normal range
(n = 29, ITT set) was high (82.8%) for both treatments and the
same number/proportion of patients presented at least one
episode of hypokalemia: 2 (6.9%) under SoC, 2 (6.9%) with
ADV7103, and 3 (10%) during both treatment periods
(Table 3).
Urine citrate and urine calcium parameters
The numbers and proport ions of responders and
non-responders for urine parameters are shown in Table 4.
Hypocitraturia was observed in 16 (94.1%) of patients with
SoC, while it was reported in only 10 (58.8%) of those under
ADV7103 (n = 17, ITT set). A total of 7 (43.8%) of the 16
non-responders experiencing hypocitraturia with SoC became
responders when switching to ADV7103, while among the 10
(58.8%) non-responders with ADV7103, only 1 (5.9%) was
previously a responder under SoC. The difference between
treatments did not reach statistical significance due to the lim-
ited number of patients in this analysis (p = 0.070).
No significant difference between treatments was observed
for hypercalciuria, as evaluated by UCa/UCr ratio. Only 3
patients presented hypercalciuria, 1 with SoC, 1 under
ADV7103, and 1 during both treatment periods.
Regarding UCa/UCi ratio, 9 (56.3%) of the 16 patients
with values above the threshold for risk of lithogenesis with
SoC had values below the threshold with ADV7103, while
from the 8 patients above the threshold with ADV7103, only 1
was below the threshold with SoC. The difference between the
proportions was statistically significant (McNemar’s p =
0.021, n = 20 evaluable patients, ITT set).
Acceptability, tolerability, and safety
Parameters of acceptability, such as ease of administration and
ease of swallowing, were improved or preserved, under
ADV7103 compared to SoC. Palatability was significantly
improved with ADV7103 when compared to SoC, with an
overall mean difference (95% CI) of 25 (10.7, 39.2) mm in
the VAS. As shown in Fig. 4a, the proportion of patients who
expressed some degree of dislike (very much or a little) was
higher with SoC than with ADV7103: 40% (14/35) vs. 3.2%
(1/31). Conversely, the proportion of patients who expressed a
like for the taste of their medication (a little or very much) was
higher with ADV7103 than with SoC: 67.7% (21/31) vs.
37.1% (13/35).
There were no AEs leading to drug discontinuation and no
deaths reported during the study. Comparing steady state
treatments, the proportion of patients who experienced at least
one AE was similar between patients receiving ADV7103
(18.8%, 6/32) and those receiving SoC (18.9%, 7/37) but the
propor t ion of pa t ien t s wi th AEs cons idered as
treatment-related was lower under ADV7103 (3.1%, 1/32)
than under SoC (10.8%, 4/37).
The proportion of patients experiencing gastrointestinal
AEs was lower during steady state treatment with ADV7103
than with SoC (3.1% vs. 13.5%). This was in agreement with
significantly reduced gastrointestinal discomfort scores with
ADV7103 when compared to SoC, with a mean difference
(95% CI) of − 14.2 (− 25.9, − 2.6) mm in the VAS. The num-
ber of patients indicating any gastrointestinal discomfort was
reduced by 50% under ADV7103 (25%, 8/32) as compared to
SoC (48.6%, 17/35), as shown in Fig. 4b.
No safety issues were reported for laboratory parameters,
physical examination, and vital signs. Only one child present-
ed with an isolated and transient episode of mild hyperkalemia
(4.7 mmol/L, for a normal range of 3.5–4.5 mmol/L according
to the corresponding local laboratory) under ADV7103.
Discussion
Current SoC treatments are immediate-release products and
their effect is short-lived, due to prompt urinary clearance.
Therefore, the treatment is given in several daily doses to
compensate for short duration of action. Additionally, it often
induces gastrointestinal side effects, probably due to a peak
concentration of alkali load in the stomach, which may nega-
tively impact adherence and overall efficacy.
For an optimized treatment with SoC, some patients require
taking their medication during night-time. This is particularly
the case for pediatric patients who are still growing, since
chronic metabolic acidosis might impair growth velocity
through IGF1 axis disturbances and bone quality through
chronic buffer requirement [13].
Table 2 Contingency tables showing the number (%) of responders for
plasma bicarbonate values and non-responders, presenting, respectively,
mean plasma bicarbonate values (mmol/L) below the normal lower limit,
and at least one value of plasma bicarbonate values (mmol/L) below the
normal lower limit, with SoC and ADV7103
Mean plasma bicarbonate (ITT set, n = 30) ADV7103
R NR
SoC R 13 (43%) 0 (0%)
NR 14 (47%) 3 (10%)
p value < 0.001*
Plasma bicarbonate (ITT set, n = 30) ADV7103
R NR
SoC R 10 (33%) 1 (3.3%)
NR 13 (43%) 6 (20%)
p value 0.002*
NR non responders, R responders
* Significant difference (according to McNemar’s test)
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Adequate metabolic control is essential for maintaining
growth velocity and bone quality in pediatric patients with
dRTA, and adequately treated children have been demonstrat-
ed to present significantly increased height values compared
with those who are inadequately treated. It is also essential to
limit nephrocalcinosis and nephrolithiasis, as well as the con-
sequences of hypokalemia [25].
With only two daily administrations of ADV7103, plasma
bicarbonate values were improved, with a more prominent
benefit in pediatric patients, who presented particularly sub-
optimal values with SoC. The clinical benefit of ADV7103 is
indicated by the reduction in the number of non-responders
with plasma bicarbonate below the normal range when
switching from SoC to the prolonged-release formulation.
The rate of non-responders with current SoC treatments in
our study is in agreement with that reported in a recent multi-
center survey including data from 340 patients with dRTA,
where only 57% of the patients showed plasma bicarbonate
values ≥ 22 mmol/L [11]. In comparison, ADV7103 could
offer a better metabolic control of the disease, according to
the high percentage of patients (90%) ultimately presenting
normal mean plasma bicarbonate values. The improved ability
to correct metabolic acidosis with ADV7103 could be associ-
ated with the possibility of optimizing dosing due to its
prolonged-release formulation, while poor tolerability and
Fig. 3 Steady state mean (± SD)
plasma potassium levels in the
different age groups before
administration of the first
morning dose of SoC (multiple
daily intakes) and ADV7103
(morning and evening), ITT set.
Blue bars: SoC, orange bars:
ADV7103
Table 4 Contingency tables showing the number (%) of responders for
calciuria, citraturia, and urine calcium/citrate ratio and non-responders,
presenting, respectively, at least one episode of UCa:UCr ratio
(mmol/mmol) above the normal upper limit, at least one episode of
UCi:UCr ratio (mmol/mmol) below the normal lower limit, and at least
one value of UCa:UCi ratio (mmol/mmol) above the threshold considered
for the risk of lithogenesis, with SoC and ADV7103
Calciuria
UCa/UCr (ITT set, n = 30) ADV7103
R NR
SoC R 27 (90%) 1 (3.3%)
NR 1 (3.3%) 1 (3.3%)
p value 1.000
Citraturia
UCi/UCr (ITT set, n = 17) ADV7103
R NR
SoC R 0 (0%) 1 (5.9%)
NR 7 (41%) 9 (53%)
p value 0.070
Urine calcium/citrate ratio
UCa/UCi (ITT set, n = 20) ADV7103
R NR
SoC R 3 (15%) 1 (5.0%)
NR 9 (45%) 7 (35%)
p value 0.021*
NR non responders, R responders
* Significant difference (according to McNemar’s test)
Table 3 Contingency table showing the number (%) of responders for
plasma potassium values and non-responders, presenting and at least one
value of plasma potassium (mmol/L) below the normal lower limit, with
SoC and ADV7103
Plasma potassium (ITT set, n = 29) ADV7103
R NR
SoC R 22 (76%) 2 (6.9%)
NR 2 (6.9%) 3 (10%)
p value 1.000
NR non responders, R responders
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acceptability seem to limit further dosing increases with SoC.
However, doses remain in agreement with the literature and
among patients with dRTA, young children typically need
higher doses than older children and adults [11].
Hypokalemia may persist in some patients despite
sustained correction of systemic acidosis with SoC alkali ther-
apy [26, 27] and these patients require potassium supplemen-
tation to maintain normal plasma potassium levels [28]. This
justifies the treatment with potassium salts in ADV7103,
which allows increasing plasma potassium without risk of
hyperkalemia.
Potassium salts are preferred over sodium salts as the for-
mer have been shown to reduce urine calcium excretion, while
the latter do not seem to affect urine calcium levels due to the
effect of sodium on renal calcium reabsorption, although both
increase urine citrate excretion levels [29].
Reduced urine citrate excretion and increased urine cal-
cium excretion are contributing factors to stone-forming
activity [25, 30, 31]. ADV7103 could also reduce the risk
of stone formation in patients with dRTA by virtue of a
better control of urine calcium and citrate excretion, as the
difference between treatments in terms of urine calcium/
citrate ratio was statistically significant in favor of the new
treatment. In a previous study in healthy subjects, de-
creased urine calcium and increased urine citrate concen-
trations were observed with ADV7103 at doses ranging
from 1 to 2.9 mEq/kg of alkali per day [18]. The present
study confirms the increased urine citrate levels with
ADV7103 in patients with dRTA, despite their need of
b u f f e r s i n b l o o d , a n d a lmo s t h a l f ( 4 4% ) o f
non-responders for citraturia under SoC became re-
sponders under ADV7103. The percentage of patients with
hypercalciuria was low (6.6%) with both treatments, as
compared to 15% of patients with dRTA with reported
hypercalciuria in an international patient cohort [11].
In conclusion, compared to SoC treatments, the
prolonged-release combination of potassium citrate and potas-
sium bicarbonate (ADV7103) significantly improves plasma
bicarbonate levels and increases the response rate (from 43 to
90%) in patients with dRTA, whilemaintaining adequate plas-
ma potassium levels. Normal levels of the urine calcium/
citrate ratio obtained when switching to ADV7103 adds to
the benefits of the prolonged-release formulation by reducing
the factors inducing a risk of extensive nephrocalcinosis and
stone formation. In addition to the control of metabolic acido-
sis, dosing scheme, acceptability, and gastrointestinal safety
profiles are improved, bringing clinical benefit and supporting
the use of ADV7103 as a first-line treatment for dRTA in
adults and children over 6 months of age. Further evaluations
are required to assess efficacy, safety, and adherence with
ADV7103 in the long-term.
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